2025-11-30 - Analysis Report
Here's a breakdown of Eli Lilly and Co (LLY) based on the provided data, with analysis:

**1. Return Rate Comparison:**

*   **Company Overview:** Eli Lilly and Co. is a pharmaceutical company focused on developing and marketing medications.
*   **LLY Cumulative Return:** 309.45%
*   **VOO (S&P 500) Cumulative Return:** 101.92%
*   **Divergence:** 208.8 (Relative Divergence: 85.9)

**Analysis:**

LLY has significantly outperformed the S&P 500. The cumulative return is more than triple that of the market index. The divergence indicates a substantial performance gap. The high relative divergence (85.9) suggests that the current outperformance is near the higher end of its historical range relative to the S&P 500.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD    | Alpha   | Beta   | Cap(B) |
|------------|---------|--------|---------|--------|--------|
| 2015-2017  | 11.0%   | 76.1%  | -17.0%  | -0.0   | 75.7   |
| 2016-2018  | 39.0%   | 68.9%  | 24.0%   | -0.0   | 103.7  |
| 2017-2019  | 41.0%   | 68.9%  | 19.0%   | 0.4    | 117.8  |
| 2018-2020  | 34.0%   | 79.8%  | 10.0%   | 0.4    | 151.4  |
| 2019-2021  | 53.0%   | 79.8%  | 7.0%    | 0.5    | 247.6  |
| 2020-2022  | 64.0%   | 79.8%  | 65.0%   | 0.4    | 328.0  |
| 2021-2023  | 125.0%  | 78.9%  | 124.0%  | 0.2    | 522.6  |
| 2022-2024  | 134.0%  | 81.2%  | 113.0%  | 0.2    | 692.1  |
| 2023-2025  | 201.0%  | 83.5%  | 134.0%  | 0.2    | 964.1  |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate has increased significantly over the periods, demonstrating strong growth momentum.
*   **MDD:** The Maximum Drawdown (MDD) is high, indicating significant volatility and potential for large price declines.
*   **Alpha:** Alpha, which measures the excess return compared to the benchmark, is significantly positive, and increasing, especially in recent periods (2020-2025). This confirms LLY's strong outperformance.
*   **Beta:** The Beta is relatively low and stable (close to zero in past periods, 0.2~0.5 recently), suggesting LLY's price movements are not strongly correlated with the overall market, potentially offering diversification benefits.
*   **Cap:** The market capitalization (Cap) has grown exponentially.

**2. Recent Stock Price Fluctuations:**

*   **Current Close:** 1075.47
*   **Previous Close:** 1104.34
*   **Change:** -2.61%
*   **5-day SMA:** 1083.92
*   **20-day SMA:** 1004.06
*   **60-day SMA:** 861.07

**Analysis:**

The stock price closed lower than its previous close. The 5-day SMA is above the 20-day SMA, which is above the 60-day SMA, suggesting a continued upward trend overall, although the price is currently declining. The current price is well above all moving averages.

**3. Indicators Analysis:**

*   **MRI (Market Risk Indicator):** 0.9 (High Investment Recommended)
*   **RSI (Relative Strength Index):** 81.50 (Overbought)
*   **PPO (Percentage Price Oscillator):** 0.164
*   **Hybrid Signal:** Buy 100% of cash
*   **Recent Relative Divergence Change:** 6.0 (+), suggesting short-term increase.
*   **Expected Return:** 46.5% (Long-term excess return vs. S&P 500)

**Analysis:**

*   The high MRI score suggests a favorable investment environment based on the model's criteria.
*   The RSI indicates that the stock is currently overbought, which could signal a potential pullback or consolidation.
*   The PPO confirms the upward momentum.
*   The Hybrid signal recommends a "Buy" position.
*   The significant expected return further supports a positive outlook for the stock's future performance.

**4. Recent News & Significant Events:**

*   **Stock Split Watch:** Potential stock split due to high share price.
*   **S&P 500 Gains and Losses:** Notes a slide in Eli Lilly stock.
*   **JPMorgan Analyst Recommendation:** Positive analyst coverage.
*   **$1 Trillion Market Cap:** Eli Lilly joins the $1 trillion market cap club.
*   **Top Analyst Price Target:** High price target from a top analyst.
*   **Opinions on $1 Trillion Milestone:** Discussion of the market cap milestone.

**Analysis:**

The news indicates significant positive momentum (reaching $1 trillion market cap, positive analyst ratings, high price targets). A potential stock split suggests the company believes the price is too high for retail investors. The mention of a stock slide in one headline indicates short-term volatility.

**4-2. Analyst Opinions:**

*   **Consensus:** Buy (Mean: 1.77)
*   **Target Price:** Average: $1024.00, High: $1500.00, Low: $770.00
*   **Recent Rating Changes:** Not provided

**Analysis:**

The analyst consensus is "Buy" with a substantial upside potential based on the average and high target prices. However, the wide range between the high and low target prices suggests differing opinions among analysts.

**5. Recent Earnings Analysis:**

| 날짜       | EPS  | 매출       |
|------------|------|------------|
| 2025-10-30 | 6.22 | 17.60 B$   |
| 2025-08-07 | 6.3  | 15.56 B$   |
| 2025-05-01 | 3.07 | 12.73 B$   |
| 2024-10-30 | 1.08 | 11.44 B$   |
| 2025-10-30 | 1.08 | 11.44 B$   |

**Analysis:**

Both EPS (Earnings Per Share) and revenue have been increasing significantly over the past few quarters. This demonstrates strong financial performance and growth.

**6. Financial Information:**

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-09-30   | $17.60B   | 82.91%        |
| 2025-06-30   | $15.56B   | 84.27%        |
| 2025-03-31   | $12.73B   | 82.53%        |
| 2024-12-31   | $13.53B   | 82.24%        |
| 2024-09-30   | $11.44B   | 81.02%        |

**Capital and Profitability:**

| Quarter      | Equity     | ROE    |
|--------------|------------|--------|
| 2025-09-30   | $23.79B   | 23.46% |
| 2025-06-30   | $18.27B   | 30.98% |
| 2025-03-31   | $15.76B   | 17.50% |
| 2024-12-31   | $14.19B   | 31.07% |
| 2024-09-30   | $14.24B   | 6.81%  |

**Analysis:**

*   **Revenue:** Revenue has shown a strong upward trend over the past year, indicating growing sales and market demand for LLY's products.
*   **Profit Margin:** The consistently high profit margin (above 80%) demonstrates the company's pricing power and efficient cost management.
*   **Equity:** Equity has been steadily increasing, reflecting the company's growing net worth.
*   **ROE (Return on Equity):** ROE is volatile but generally high, indicating efficient use of shareholder equity to generate profits.

**7. Comprehensive Analysis (Summary):**

Eli Lilly and Co. (LLY) demonstrates very strong financial performance and market sentiment.

*   **Performance:** LLY has significantly outperformed the S&P 500 with a high cumulative return and alpha.
*   **Growth:** Revenue, EPS, and market capitalization are all growing rapidly.
*   **Profitability:** The company maintains high profit margins and ROE.
*   **Market Sentiment:** Analyst ratings are positive, and the stock recently joined the $1 trillion market cap club.
*   **Risk:** The RSI indicates the stock is overbought, and the high MDD suggests potential volatility. The recent price decline, though small, may also indicate the end of the uptrend.

**Overall Recommendation:**

Based on the provided data, LLY appears to be a strong investment with high growth potential. However, investors should be aware of the overbought condition and potential for volatility. A potential stock split could make the stock more accessible to retail investors.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.